Cancer Therapies: Technologies and Global Markets

Home
Medical Equipment and Supplies
Healthcare
Cancer Therapies: Technologies and Global Markets

Cancer Therapies: Technologies and Global Markets

Price:

USD $4,850.00

ISBN/SKU #:

GB-HLC027B

Research Group:

BCC

Date of Publication:

May 2008

Summary

The goal for conducting Cancer Therapies study is to provide an overview of the current and potential aspects of the global market for cancer therapies. The report determines the market size, market leaders, and factors affecting the market for cancer therapies with the inclusion of the market by disease sector.

The overview of types of diseases and different therapies in cancer is also examined along with sale figures over the 5-year period from 2008 to 2013. Companies manufacturing/selling the drugs to treat cancer are profiled, and the factors affecting markets for these products and how those markets are likely to change are analyzed. Revenues have been broken down by the type of therapies and by different regions.

Our key objective is to present a comprehensive analysis of the current and future market and to analyze the future direction of cancer therapies with an emphasis on newer products.

This Report:

Covers updated aspects in the oncology industry
Reviews markets for each of the categories of reagents used to treat cancer and different therapies, including chemotherapy, immunotherapy, target therapy, and sex hormones
Analyzes spending in the reagents and therapies categories worldwide
Studies new and different types of regulations enforced by the authorities in the oncology field, new drugs, and recalls in the market
Studies the market share of the different drug manufacturers and suppliers with an emphasis on the market leaders, as well as demand and use
Emphasizes new technologies and their uses
Examines new patents and their significance with a statistical description
Details present and future (2013) trends in spending in the cancer therapy

Due to continuous technology advances in research and development in the field of oncology and the requirement for newer and more effective pharmaceutical drugs/therapies, companies are investing in the development of these new products to lessen the side effects and target the disease. A fundamental change in cancer therapies is underway with a shift from the use of chemotherapy drugs to targeted therapy or the use of chemotherapy drugs along with targeted therapies. Targeted therapies are being developed for targeting cancer cells more specifically. Targeted therapies are more efficacious and less toxic than chemotherapy due to their more selective nature.

This study looks at almost all types of therapies/products used in oncology. The study conducts the prevalence of cancer globally. The research and development of new products and major changes in market behavior justify focusing on this segment. Finally, this study discusses the usage of these drug therapies by disease sector to determine the usage in each sector. The study contributes to the areas of market growth and decline in cancer therapies from the point of view of manufacturers and users. This study will be of interest largely to the pharmaceutical and biopharmaceutical industries, clinics, and hospitals.

The scope of this study encompasses the markets for cancer therapies. BCC analyzes each market and its market leaders; different types of therapies; the prevalence of cancer; the regulatory environment; the different disease sectors for cancer; and market projections and market share. Technological issues include the latest trends and new developments

Both primary and secondary sources were used for this research. A comprehensive literature search was conducted. The literature included technical newsletters and journals as well as many other sources. The data were collected through interviews and correspondence with various pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, likely unit prices, rates of consumption, and market trends.

TABLE OF CONTENTS

Chapter- 1: SUMMARY

SUMMARY TABLE THE GLOBAL CANCER THERAPY MARKET, THROUGH 2013 ($ MILLIONS)

SUMMARY FIGURE THE GLOBAL CANCER THERAPY MARKET, 2006-2013 ($ MILLIONS)

Chapter- 2: OVERVIEW

WHAT IS CANCER?

CAUSES OF CANCER

TYPES OF CANCER

BLADDER CANCER

Risk Factors

Treatment

BREAST CANCER

Risk Factors

Treatment

COLORECTAL CANCER

Risk Factors

Treatment

ENDOMETRIAL CANCER

Risk Factors

Treatment

KIDNEY CANCER

Risk Factors

Treatment

LEUKEMIA

Risk Factors

Treatment

LUNG CANCER

Risk Factors

Treatment

MELANOMA

Risk Factors

Treatment

NON-HODGKIN’S LYMPHOMA

Risk Factors

Treatment

PANCREATIC CANCER

Risk Factors

Treatment

PROSTATE CANCER

Risk Factors

Treatment

SKIN CANCER

Risk Factors

Treatment

THYROID CANCER

Risk Factors

Treatment

Chapter- 3: REGULATORY ISSUES

NEW DRUG APPROVALS

TABLE 1 CANCER DRUGS APPROVED BY THE FDA

NEW DRUG APPLICATIONS

TABLE 2 NEW DRUG APPLICATIONS (2005 TO JANUARY 2008)

RECALLS

TABLE 3 RECALLS (2005 TO JANUARY 2008)

Chapter- 4: PREVALENCE

WORLDWIDE PREVALENCE

TABLE 4 WORLDWIDE PREVALENCE OF CANCER, 2007 (MILLIONS)

TABLE 5 WORLDWIDE PREVALENCE OF NEW CASES OF CANCER, BY REGION, 2007

TABLE 6 WORLDWIDE DEATHS DUE TO CANCER, BY REGION, 2007

PREVALENCE IN THE UNITED STATES

TABLE 7 ESTIMATED NEW CANCER CASES IN THE U.S., 2007

TABLE 8 CANCER DEATHS IN THE U.S., 2007

PREVALENCE IN EUROPE

TABLE 9 ESTIMATED NEW CANCER CASES IN EUROPE, 2007

TABLE 10 CANCER DEATHS IN EUROPE, 2007

Chapter- 5: CLASSIFICATION OF CANCER THERAPIES

CHEMOTHERAPY

ALKYLATING AND ALKYLATING-LIKE AGENTS

TABLE 11 ALKYLATING AGENTS

ANTIMETABOLITES

TABLE 12 ANTIMETABOLITES

ANTHRACYCLINES

TABLE 13 CYTOTOXIC ANTIBIOTIC DRUGS

PLANT ALKALOIDS

TABLE 14 ALKALOIDS/MITOTIC INHIBITORS

TOPOISOMERASE INHIBITORS

TABLE 15 TOPOISOMERASE INHIBITORS

BIOLOGICAL THERAPY OR IMMUNOTHERAPY

INTERFERONS AND OTHER CYTOKINES

TABLE 16 INTERFERONS USED IN CANCER THERAPY

TABLE 17 INTERLEUKINS USED IN CANCER THERAPY

CANCER VACCINES

HORMONE THERAPY

ANTIESTROGENS

TABLE 18 ANTIESTROGENS USED IN CANCER THERAPY

AROMATASE INHIBITOR

TABLE 19 AROMATASE INHIBITORS USED IN THE TREATMENT OF CANCER

ANTIANDROGENS

TABLE 20 ANTIANDROGENS USED IN CANCER TREATMENT

LUTEINIZING HORMONE-RELEASING HORMONE

TABLE 21 LUTEINIZING HORMONE-RELEASING HORMONE USED IN THE TREATMENT OF CANCER

TARGETED THERAPY

SMALL MOLECULES/CANCER GROWTH INHIBITORS

TABLE 22 CANCER GROWTH INHIBITORS

MONOCLONAL ANTIBODIES

Conjugated

Naked

TABLE 23 MONOCLONAL ANTIBODIES USED IN THE TREATMENT OF CANCER

Chapter- 6: INDUSTRY STRUCTURE

CHEMOTHERAPY

ALKYLATING AGENTS

TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)

FIGURE 1 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)

ANTHRACYCLINES

TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)

FIGURE 2 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)

PLANT ALKALOIDS

TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)

FIGURE 3 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)

ANTIMETABOLITES

TABLE 27 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)

FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)

TOPOISOMERASE

TABLE 28 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)

FIGURE 5 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)

MARKET LEADERS OF CHEMOTHERAPY

TABLE 29 WORLDWIDE MARKET SHARE IN CHEMOTHERAPY, 2007 (%)

FIGURE 6 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CHEMOTHERAPY, 2007 (%)

HORMONE THERAPY

ANTIESTROGENS

TABLE 30 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)

FIGURE 7 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)

ANTIANDROGENS

TABLE 31 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)

FIGURE 8 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIENDROGENS, 2007 (%)

AROMATASE INHIBITORS

TABLE 32 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)

FIGURE 9 SHARES OF MANUFCATURERS/DISTRIBUTORS FOR AROMATASE INHIBITOR, 2007 (%)

LH-RH AGONIST INHIBITORS

TABLE 33 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH-RH AGONIST INHIBITORS, 2007 (%)

FIGURE 10 SHARES OF MANUFACTURERS/ DISTRIBUTORS FOR LH RH AGONIST INHIBITORS, 2007 (%)

MARKET LEADERS OF HORMONE THERAPY

TABLE 34 WORLDWIDE MARKET SHARE IN HORMONE THERAPY, 2007 (%)

FIGURE 11 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR HORMONE THERAPY, 2007 (%)

TARGETED THERAPY

MONOCLONAL ANTIBODIES

TABLE 35 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%)

FIGURE 12 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%)

SMALL MOLECULES

TABLE 36 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%)

FIGURE 13 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%)

MARKET LEADERS OF TARGET THERAPY

TABLE 37 WORLDWIDE MARKET SHARE IN TARGET THERAPY, 2007 (%)

FIGURE 14 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TARGET THERAPY, 2007 (%)

IMMUNOTHERAPY

INTERFERON AND CYTOKINES

TABLE 38 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%)

FIGURE 15 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%)

CANCER VACCINES

TABLE 39 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%)

FIGURE 16 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%)

MARKET LEADERS OF IMMUNOTHERAPY

TABLE 40 WORLDWIDE MARKET SHARE IN IMMUNOTHERAPY, 2007 (%)

FIGURE 17 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR IMMUNOTHERAPY, 2007 (%)

DEMAND AND USE

FACTORS AFFECTING SALES OF CANCER DRUGS

Competition

Pricing/Cost

MAJOR FACTORS FOR FUTURE GROWTH

Life Expectancy

Patent Protection

Drug Portfolio Management

Significant Potential of Developing Countries

FUTURE OF THE CANCER MARKET

Chemotherapy Will Sustain

Targeted Therapy dominates

Patent Expiries

STRATEGIES OF BIG PHARMACEUTICAL COMPANIES

Enhancement in Production Capacity:

Market Strategy

Mergers, Acquisitions, and Collaborations

Further Investigations

Chapter- 7: MARKET ANALYSIS

CHEMOTHERAPY

Market Size

TABLE 41 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, THROUGH 2013 ($ MILLIONS)

FIGURE 18 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, 2006-2013 ($ MILLIONS)

TABLE 42 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)

FIGURE 19 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)

ALKYLATING AGENTS

TABLE 43 GLOBAL SALES OF ALKYLATING AGENTS, THROUGH 2013 ($ MILLIONS)

FIGURE 20 GLOBAL SALES OF ALKYLATING AGENTS, 2006-2013 ($ MILLIONS)

ANTHRACYCLINES

TABLE 44 GLOBAL SALES OF ANTHRACYCLINES, THROUGH 2013 ($ MILLIONS)

FIGURE 21 GLOBAL SALES OF ANTHRACYCLINES, 2006-2013 ($ MILLIONS)

PLANT ALKALOIDS

TABLE 45 GLOBAL SALES OF PLANT ALKALOIDS, THROUGH 2013 ($ MILLIONS)

FIGURE 22 GLOBAL SALES OF PLANT ALKALOIDS, 2006-2013 ($ MILLIONS)

ANTIMETABOLITES

TABLE 46 GLOBAL SALES OF ANTIMETABOLITES, THROUGH 2013 ($ MILLIONS)

FIGURE 23 GLOBAL SALES OF ANTIMETABOLITES, 2006-2013 ($ MILLIONS)

TOPOISOMERASE INHIBITORS

TABLE 47 GLOBAL SALES OF TOPOISOMERASE INHIBITORS, THROUGH 2013 ($ MILLIONS)

FIGURE 24 GLOBAL SALES OF TOPISOMERASE INHIBITORS, 2006-2013 ($ MILLIONS)

HORMONE THERAPY

Market Size

TABLE 48 GLOBAL SALES OF HORMONE THERAPIES, THROUGH 2013 ($ MILLIONS)

FIGURE 25 GLOBAL SALES OF HORMONE THERAPIES, 2006-2013 ($ MILLIONS)

TABLE 49 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)

FIGURE 26 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)

ANTIESTROGENS

TABLE 50 GLOBAL SALES OF ANTIESTROGENS, THROUGH 2013 ($ MILLIONS)

FIGURE 27 GLOBAL SALES OF ANTIESTROGENS, 2006-2013 ($ MILLIONS)

ANTIANDROGENS

TABLE 51 GLOBAL SALES OF ANTIANDROGENS, THROUGH 2013 ($ MILLIONS)

FIGURE 28 GLOBAL SALES OF ANTIANDROGENS, 2006-2013 ($ MILLIONS)

AROMATASE INHIBITORS

TABLE 52 GLOBAL SALES OF AROMATASE INHIBITORS, THROUGH 2013 ($ MILLIONS)

FIGURE 29 GLOBAL SALES OF AROMATASE INHIBITORS, 2006-2013 ($ MILLIONS)

LH-RH AGONISTS

TABLE 53 GLOBAL SALES OF LH-RH AGONISTS, THROUGH 2013 ($ MILLIONS)

FIGURE 30 GLOBAL SALES OF LH-RH AGONISTS, 2006-2013 ($ MILLIONS)

TARGET THERAPIES

Market Size

TABLE 54 GLOBAL SALES OF TARGET THERAPY CANCER PRODUCTS, THROUGH 2013 ($ MILLIONS)

FIGURE 31 WORLDWIDE SALES OF TARGET THERAPY CANCER PRODUCTS, 2006-2013 ($ MILLIONS)

TABLE 55 GLOBAL SHARE OF TARGETED THERAPY, BY TYPE, 2007 (%)

FIGURE 32 GLOBAL SHARE OF TARGET THERAPY, BY TYPE, 2007 (%)

MONOCLONAL ANTIBODIES

TABLE 56 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2013 ($ MILLIONS)

FIGURE 33 GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2006-2013 ($ MILLIONS)

SMALL MOLECULES

TABLE 57 GLOBAL SALES OF SMALL MOLECULES, THROUGH 2013 ($ MILLIONS)

FIGURE 34 GLOBAL SALES OF SMALL MOLECULES, 2006-2013 ($ MILLIONS)

IMMUNOTHERAPY

Market Size

TABLE 58 GLOBAL SALES OF IMMUNOTHERAPY PRODUCTS, THROUGH 2013 ($ MILLIONS)

FIGURE 35 WORLDWIDE SALES OF IMMUNOTHERAPY PRODUCTS, 2006-2013 ($ MILLIONS)

TABLE 59 GLOBAL REVENUE SHARE OF IMMUNOTHERAPY BY TYPE, 2007 (%)

FIGURE 36 GLOBAL SHARE OF IMMUNOTHERPY, BY TYPE, 2007 (%)

INTERFERONS AND CYTOKINES

TABLE 60 GLOBAL SALES OF INTERFERONS AND CYTOKINES, THROUGH 2013 ($ MILLIONS)

FIGURE 37 GLOBAL SALES OF INTERFERONS AND CYTOKINES, 2006-2013 ($ MILLIONS)

VACCINES

TABLE 61 GLOBAL SALES OF CANCER VACCINES, THROUGH 2013 ($ MILLIONS)

FIGURE 38 GLOBAL SALES OF CANCER VACCINES, 2006-2013 ($ MILLIONS)

Chapter- 8: NEW DEVELOPMENTS

NEW DEVELOPMENTS

TABLE 62 CANCER DRUG PIPELINE IN PHASE III CLINICAL TRIALS

TARGET

TABLE 63 CANCER DRUG PIPELINE IN PHASE II CLINICAL TRIALS

TABLE 64 CANCER DRUG PIPELINE IN PHASE I CLINICAL TRIALS

Chapter- 9: MARKET BY DISEASE TYPE

TABLE 65 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, THROUGH 2013 ($ MILLIONS)

FIGURE 39 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, 2006-2013 ($ MILLIONS)

TABLE 66 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)

FIGURE 40 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)

BREAST CANCER THERAPY

TABLE 67 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 ($ MILLION/%)

FIGURE 41 SALES OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 ($ MILLIONS)

TABLE 68 WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)

FIGURE 42 WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)

COLORECTAL CANCER

TABLE 69 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007 ($ MILLION/%)

FIGURE 43 SALES OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007 ($ MILLIONS)

TABLE 70 WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)

FIGURE 44 WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)

PROSTATE CANCER

TABLE 71 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 ($ MILLION/%)

FIGURE 45 SALES OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 ($ MILLIONS)

TABLE 72 WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)

FIGURE 46 WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)

NONSMALL CELL LUNG CANCER

TABLE 73 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007 ($ MILLIONS/%)

FIGURE 47 GLOBAL SALES OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007 ($ MILLIONS)

TABLE 74 GLOBAL MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)

FIGURE 48 WORLDWIDE MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)

HEAD AND NECK CANCER

TABLE 75 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 ($ MILLION/%)

FIGURE 49 GLOBAL SALES OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 ($ MILLIONS)

TABLE 76 WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)

FIGURE 50 WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)

RENAL CELL CARCINOMA

TABLE 77 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 ($ MILLIONS/%)

FIGURE 51 GLOBAL SALES OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 ($ MILLIONS)

TABLE 78 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)

FIGURE 52 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)

PANCREATIC CANCER THERAPY

TABLE 79 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 ($ MILLION/%)

FIGURE 53 GLOBAL SALES OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 ($ MILLIONS)

TABLE 80 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)

FIGURE 54 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)

Chapter- 10: PATENT ANALYSIS

TOTAL PATENTS

PATENTS BY YEAR

TABLE 81 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2008

FIGURE 55 NUMBER OF PATENTS, 2005-2008

PATENTS BY TYPE

TABLE 82 NUMBER OF PATENTS BY TYPE, 2005-2008

FIGURE 56 NUMBER OF PATENTS BY TYPE, 2005-2008 (NO. OF PATENTS)

FIGURE 57 NUMBER OF PATENTS, SHARE BY TYPE, 2005-2008 (%)

PATENTS BY COUNTRY

TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008

PATENTS BY COMPANY

TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005-2008

PATENTS BY ASSIGNEE

TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005-2008

Chapter- 11: COMPANY PROFILES

ABRAXIS BIOSCIENCES, INC.

AMGEN INC.

ASTRAZENECA PLC

BIOGEN IDEC

BRISTOL-MYERS SQUIBB

CELGENE CORP.

CEPHALON INC.

CHUGAI PHARMACEUTICAL CO., LTD.

ELI LILLY AND CO.

GENENTECH INC.

GENZYME CORP.

GLAXOSMITHKLINE PLC

GPC BIOTECH AG

IMCLONE SYSTEMS, INC.

INFINITY PHARMACEUTICALS, INC.

MERCK & CO.

NOVARTIS

OSI PHARMACEUTICALS, INC.

PFIZER INC.

PROGEN PHARMACEUTICALS, LTD.

ROCHE

SANOFI-AVENTIS

SCHERING-PLOUGH

SEATTLE GENETICS, INC.

TAP PHARMACEUTICAL PRODUCTS, INC.

TAIHO PHARMACEUTICALS CO., LTD.

WYETH

YM BIOSCIENCES, INC.

Chapter- 12: APPENDIX

APPENDIX

New Publications